BRAF and non-small cell lung carcinoma: Regarding other alterations associated with resistance to KRAS c.34G > T (p.G12C) inhibitors, among 32 NSCLC patients enrolled in Codebreak 100 and Codebreak 101, acquired resistance was identified in 78% of cases (including alterations in KRAS, NRAS, BRAF, EGFR, FGFR2, MYC and other genes).